Transport characteristics of a novel peptide platform for CNS therapeutics. - Wikidata - awgldk - TriplyDB

Transport characteristics of a novel peptide platform for CNS therapeutics.

Transport characteristics of a novel peptide platform for CNS therapeutics.

http://www.wikidata.org/entity/Q37294333

about

Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties Agile delivery of protein therapeutics to CNS A novel vascular targeting strategy for brain-derived endothelial cells using a TCR mimic antibody.Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1.The involvement of microglial cells in Japanese encephalitis infections.Taxane anticancer agents: a patent perspective.Improving the transport of chemotherapeutic drugs across the blood-brain barrier.Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer's disease?Design of brain imaging agents for positron emission tomography: do large bioconjugates provide an opportunity for in vivo brain imaging?Impact of Concanavalin-A-Mediated Cytoskeleton Disruption on Low-Density Lipoprotein Receptor-Related Protein-1 Internalization and Cell Surface Expression in Glioblastomas A novel LRP1-binding peptide L57 that crosses the blood brain barrier.Peptibodies: An elegant solution for a long-standing problem.Improving gold nanorod delivery to the central nervous system by conjugation to the shuttle Angiopep-2.On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site.

P2860

Q30572687-0FD7E62B-FB3B-478B-82EA-03B5CC01B999 Q34079647-B5337A76-0439-4D45-B828-1A3CD5440B1B Q34130082-C17EBC82-6E8B-4BEC-BA2E-FCBDD0963797 Q35623290-F441C081-000D-4CEB-A3FC-DE611F49C799 Q36167789-5C7B1E20-B813-4001-A4BF-84E5F2A7C149 Q37087888-C6140D3C-5588-4D74-BB61-0D58F31136B0 Q37960529-92366AF4-DE92-4713-9445-7700808F1A1A Q38260539-DB926F52-B1B1-4F8A-94C1-4C217B15B04A Q38683844-1E97E483-363F-43B5-92D2-B541235E06BD Q39348133-4424B5AD-C711-4FB9-84B2-46BFD6E16225 Q39735172-04730C12-74F6-470B-9837-85F0231E3281 Q45734282-7DE981A7-8269-4F04-BCF2-B03303EAC7A2 Q47229048-D0A06FE9-7563-4CD1-932C-1009443F76BE Q47960548-C1DAF441-5504-42FE-B47B-9B523D6B52EC Q55054276-F0E2B9FA-D45C-45B2-8ED0-E51CF59850C9

P2860

Transport characteristics of a novel peptide platform for CNS therapeutics.

http://www.wikidata.org/entity/Q37294333

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Transport characteristics of a novel peptide platform for CNS therapeutics.

@en

Transport characteristics of a novel peptide platform for CNS therapeutics.

@nl

type

label

Transport characteristics of a novel peptide platform for CNS therapeutics.

@en

Transport characteristics of a novel peptide platform for CNS therapeutics.

@nl

prefLabel

Transport characteristics of a novel peptide platform for CNS therapeutics.

@en

Transport characteristics of a novel peptide platform for CNS therapeutics.

@nl

P1433

Q37294333-CEA36E60-8678-4114-8EB4-5E09E28DBB8B

P1476

Q37294333-656F1AAB-2467-454A-8C94-1A7B84FEC5B9

P2093

Q37294333-16B359B4-B494-43A4-97F1-C1F75076E19F

Q37294333-211DD557-08BE-4292-97A1-594E539F8AAE

Q37294333-2986C2A3-BAA7-407F-A9C6-B968F7571922

Q37294333-4E7ABA00-3C52-412D-8EBA-AA5DAC5A8DEC

Q37294333-582ED679-5DC6-49E3-A201-DF4D206EEA3F

Q37294333-7AE17176-2CD8-498F-BBBF-7BEBFF14B03F

Q37294333-88077C6E-E807-4B20-B6DA-4512CC81570D

Q37294333-9358269B-FE6B-4A37-84AB-B5B96282865D

Q37294333-BFDB8BCD-2EAA-44BE-BC83-BA2E9DB4715E

Q37294333-C5C7D0C6-D276-4678-BCC8-03EFDD199094

P2860

Q37294333-05E975B8-08FA-4AFB-83C8-0D46D5CED85E

Q37294333-06FD0BB7-E624-4925-8395-CB99C340486B

Q37294333-0D4C3E30-A2E2-43EC-AD3D-C55DDC86CC20

Q37294333-0FCEDB16-1295-4087-AC1D-04B5547BF6D1

Q37294333-14A9CD08-620D-4EB1-9576-D5510B038B92

Q37294333-1D483324-CB41-4534-BC11-19A19EEA4948

Q37294333-1EEE3795-E405-4D0A-9B9C-46E6642A2D22

Q37294333-23951710-C3FC-42AC-BBF2-080DCE000291

Q37294333-2A8DB74A-5C6E-49BE-95FB-C9E2F42644C2

Q37294333-35E3BF8F-DEB9-44E3-83AB-E71BAAF82161

P304

Q37294333-4F4EF8E0-6F90-4C63-9531-280E3A3CFE23

P31

Q37294333-F666CFAE-CF4C-469B-B7A7-5D53C7CFFF19

P356

Q37294333-2BE3B5D9-6B57-4563-8C1F-813B83694924

P433

Q37294333-F2BB4F76-5404-4051-BC61-35344B12189E

P478

Q37294333-F755849E-67B4-47A5-902C-96A9362F3C02

P577

Q37294333-775AD1C8-060C-4B6C-A0DE-A5854F58C21B

P5875

Q37294333-13C760FC-6D66-490B-8429-08E4CFEA677B

P698

Q37294333-61F6F419-0C81-400E-A2CE-4A2E82B35C8E

P932

Q37294333-38CC8A2C-1451-46E5-BE14-60809685EB10

P356

J.1582-4934.2009.00930.X

P1433

Journal of Cellular and Molecular Medicine

P1476

Transport characteristics of a novel peptide platform for CNS therapeutics.

@en

P2093

Abedelnasser Abulrob

http://www.w3.org/2001/XMLSchema#string

Anthony Régina

http://www.w3.org/2001/XMLSchema#string

Christian Ché

http://www.w3.org/2001/XMLSchema#string

Danica Stanimirovic

http://www.w3.org/2001/XMLSchema#string

Dorothy Fatehi

http://www.w3.org/2001/XMLSchema#string

Hervé Sartelet

http://www.w3.org/2001/XMLSchema#string

Jean-Christophe Currie

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Castaigne

http://www.w3.org/2001/XMLSchema#string

Michel Demeule

http://www.w3.org/2001/XMLSchema#string

Reinhard Gabathuler

http://www.w3.org/2001/XMLSchema#string

P2860

The blood-brain barrier: bottleneck in brain drug development

The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein

Clearance of amyloid-beta by circulating lipoprotein receptors

Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2

A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases

A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein

Drug targeting to the brain

Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor

LRP: a multifunctional scavenger and signaling receptor

Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain.

P304

2827-2839

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1582-4934.2009.00930.X

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26883868

http://www.w3.org/2001/XMLSchema#string

P698

19818094

http://www.w3.org/2001/XMLSchema#string

P932

3822732

http://www.w3.org/2001/XMLSchema#string